Telix Pharmaceuticals Limited Cost Of Sales
Telix Pharmaceuticals Limited (TLPPF) reported Cost Of Sales of $377.36 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-20.
Financial Statements › Expense Statement › Cost of Sales
ifrs-full:CostOfSales · last filed 2026-02-20
AUD
| Period end | Cost Of Sales 12 month |
|---|---|
| 2024-12-31 | 273.53M AUD 20-F · filed 2025-02-24 |
| 2023-12-31 | 188.16M AUD 20-F · filed 2025-02-24 |
| 2022-12-31 | 65.17M AUD 20-F · filed 2025-02-24 |
USD
| Period end | Cost Of Sales 12 month |
|---|---|
| 2025-12-31 | $377.36M 20-F · filed 2026-02-20 |
| 2024-12-31 | $180.39M 20-F · filed 2026-02-20 |
| 2023-12-31 | $123.44M 20-F · filed 2026-02-20 |